Back to Search Start Over

Abstract 4368: High-throughput phenotyping of lung cancer somatic mutations

Authors :
Larson Hogstrom
David L. Lahr
Yashaswi Shrestha
Cong Zhu
Jesse S. Boehm
Mukta Bagul
David E. Root
Aravind Subramanian
John G. Doench
Angela N. Brooks
Atanas Kamburov
Alice H. Berger
Rajiv Narayan
Pablo Tamayo
Candace R. Chouinard
Nathan O. Kaplan
Bang Wong
Sasha Pantel
Xiaoping Yang
Todd R. Golub
Marcin Imielinski
Xiaoyun Wu
Matthew Meyerson
Itay Tirosh
Gad Getz
Ted Natoli
Federica Piccioni
Ryo Sakai
Source :
Cancer Research. 76:4368-4368
Publication Year :
2016
Publisher :
American Association for Cancer Research (AACR), 2016.

Abstract

Recent cancer genome sequencing and analysis has identified millions of somatic mutations in cancer. However, the functional impact of most variants is poorly understood, limiting the use of this genetic knowledge for clinical decision-making. Here we describe a new high-throughput approach, expression-based variant impact phenotyping (eVIP), which uses gene expression changes to infer somatic mutation impact. We generated a lentiviral expression library representing 53 genes and 194 somatic mutations identified in primary lung adenocarcinomas. Next, we introduced this library into A549 lung adenocarcinoma cells and 96 hours later performed gene expression profiling using Luminex-based L1000 profiling. We built a computational pipeline, eVIP, to compare mutant and wild-type expression signatures to infer whether variants were gain-of-function, change-of-function, loss-of-function, or neutral. Overall, eVIP identified 69% of mutations as impactful whereas 31% appeared functionally neutral. A very high rate, 92%, of missense mutations in the KEAP1 and STK11 tumor suppressor genes were found to inactivate or diminish protein function. As a complementary approach, we assessed which mutations are epistatic to EGFR or capable of initiating xenograft tumor formation in vivo. A subset of the impactful mutations identified by eVIP could induce xenograft tumor formation in mice and/or confer resistance to cellular EGFR inhibition. Among these mutations were 20 rare or non-canonical somatic variants in clinically-actionable or -relevant oncogenes including EGFR S645C, ARAF S214C and S214F, ERBB2 S418T, and PIK3CA E600K. eVIP can, in principle, characterize any genetic variant, independent of prior knowledge of gene function. Further application of eVIP should significantly advance the pace of functional characterization of mutations identified from genome sequencing. Citation Format: Alice H. Berger, Angela N. Brooks, Xiaoyun Wu, Yashaswi Shrestha, Candace Chouinard, Federica Piccioni, Mukta Bagul, Atanas Kamburov, Marcin Imielinski, Larson Hogstrom, Cong Zhu, Xiaoping Yang, Sasha Pantel, Ryo Sakai, Nathan Kaplan, David Root, Rajiv Narayan, Ted Natoli, David Lahr, Itay Tirosh, Pablo Tamayo, Gad Getz, Bang Wong, John Doench, Aravind Subramanian, Todd R. Golub, Matthew Meyerson, Jesse S. Boehm. High-throughput phenotyping of lung cancer somatic mutations. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4368.

Details

ISSN :
15387445 and 00085472
Volume :
76
Database :
OpenAIRE
Journal :
Cancer Research
Accession number :
edsair.doi...........c161de3f66ead17ff61526cb6ced57a6